Skip to main content
GeneralHomeInvestorsNews

MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement

By November 7, 2022March 15th, 2024No Comments1 min read